Table 1.

Patient cohort characteristics.

	Development (BCH, n = 214)	External Validation (CBTN, n = 112)	p-values
Age (years)			0.19*
median (range)	5 (1 – 20)	6 (1 – 21)
Sex n (%)			0.82+
Female	95 (44.4%)	51 (45.5%)
Male	113 (52.8%)	55 (49.1%)
Unknown	6 (2.8%)	4 (3.6%)
Race/Ethnicity n (%)			1.076e-06+
Non-Hispanic Caucasian/white	145 (67.8%)	71 (64.5%)
African American/Black	6 (2.8%)	14 (12.7%)
Hispanic/Latinx	3 (1.4%)	10 (9.1%)
Asian American/Asian	9 (4.2%)	3 (2.7%)
American Indian/Alaska Native	0	1 (0.9%)
More than once race	0	1 (0.9%)
Other/Unknown	51 (23.8%)	10 (9.1%)
Histologic diagnosis n (%)			0.0005+
Pilocytic Astrocytoma	52 (24.2%)	68 (61.8%)
Fibrillary Astrocytoma	0	8 (7.3%)
Pilomyxoid Astrocytoma	8 (3.7%)	17 (15.5%)
Ganglioglioma	13 (6.1%)	0
Dysembryoplastic neuroepithelial tumor	7 (3.3%)	0
Diffuse Astrocytoma	1 (0.5%)	7 (6.4%)
Angiocentric Glioma	1 (0.5%)	1 (0.9%)
Other Low-Grade Glioma/Astrocytoma	132 (61.7%)	9 (8.2%)
BRAF Mutation Status n (%)			0.0005+
V600E	50 (23.4%)	17 (15.2%)
Fusion	60 (28.0%)	60 (53.6%)
Wildtype	104 (48.6%)	35 (31.3%)
Tumor Locations n (%)			0.0005+
Cerebellum/Posterior fossa	40 (18.7%)	33 (29.4%)
Temporal lobe	43 (20.1%)	12 (10.7%)
Frontal Lobe	22 (10.3%)	4 (3.6%)
Suprasellar	6 (2.8%)	32 (28.6%)
Optic Pathway	8 (3.7%)	17 (14.9%)
Brainstem	7 (3.3%)	9 (7.9%)
Thalamus	15 (7.0%)	2 (1.8%)
Ventricles	14 (6.5%)	2 (11.4%)
Others	59 (27.6%)	1 (0.9%)

CBTN: Children Brain Tumor Network. The Kruskal-Wallis rank sum test (*) was performed for numerical data age to test the statistical significance between age medians. The Fisher’s Exact test (+) was performed for categorical data to test the statistical significance differences between CBTN and BCH datasets. A p-value less than 0.05 is statistically significant.